Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Polish Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lopate, G.
Right arrow Articles by Clifford, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lopate, G.
Right arrow Articles by Clifford, D.
NEUROLOGY 2005;64:1632-1634
© 2005 American Academy of Neurology
Brief Communications

Anti-sulfatide antibodies in HIV-infected individuals with sensory neuropathy

G. Lopate, MD, A. Pestronk, MD, S. Evans, PhD, L. Li, BS and D. Clifford, MD

From the Department of Neurology (Drs. Lopate Pestronk, and Clifford), Washington University, St. Louis, MO; and Department of Biostatistics (Dr. Evans and L. Li), Harvard University, Boston, MA.

Address correspondence and reprint requests to Dr. Glenn Lopate, Department of Neurology, Washington University School of Medicine, Box 8111, 660 South Euclid Avenue, St. Louis, MO 63110; e-mail: lopateg{at}neuro.wustl.edu

We used ELISA to estimate the prevalence of anti-sulfatide antibodies in HIV-infected individuals with distal sensory neuropathy (DSP) and compared the results with the prevalence in HIV-infected individuals without DSP and in individuals with neuropathy who are not infected with HIV. We found that 36% of HIV+/DSP+ individuals had immunoglobulin (Ig) G anti-sulfatide antibody titers greater than 1,500, whereas IgG anti-sulfatide antibodies were rarely found in HIV+/DSP– or HIV–/DSP+ patients.

Dr. Evans was supported by the NIH Statistical and Data Management Center grant number 5 U01 AI038855-08 and the Neurologic AIDS Research Consortium grant 2 U01 NS0322228-08A1. Dr. Clifford was supported by grants NS322228, AI25903, and NIMH-22005. ACTG 291 (Dr. Justin McArthur, PI), which contributed specimens to analysis was funded by the ACTG (AI38858) and by the Neurologic AIDS Research Consortium (NS32228). Drs. Lopate and Pestronk were supported by a grant from the Washington University Neuromuscular Research Fund.

Received August 19 2004. Accepted in final form January 21, 2005.




This article has been cited by other articles:


Home page
 GlycobiologyHome page
K. Townson, K. N Greenshields, J. Veitch, D. Nicholl, M. Eckhardt, O. Galanina, N. Bovin, E. Samain, T. Antoine, D. Bundle, et al.
Sulfatide binding properties of murine and human antiganglioside antibodies
Glycobiology, November 1, 2007; 17(11): 1156 - 1166.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.